IC
ADMA icon

Inscription Capital’s ADMA Biologics ADMA Stock Holding History

Inscription Capital’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111K Sell
13,204
-209
-2% -$1.91K 0.01% 769
2026
Q1 		$121K Buy
+13,413
New +$212K 0.01% 668

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Inscription Capital's ADMA Position: Q2 2026 in Review

Inscription Capital reduced its ADMA Biologics (ADMA) stake by 1.6% in Q2 2026, selling an estimated $1.91K and leaving 13,204 shares worth $111K. The position accounts for 0.01% of the portfolio, ranked #769.

Inscription Capital first reported a position in ADMA in Q1 2026 and has held it in 2 quarters since. The position peaked at $121K in Q1 2026. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Inscription Capital held 13,204 shares of ADMA Biologics worth $111K as of Q2 2026.
  • Inscription Capital sold 209 ADMA Biologics shares in Q2 2026, an estimated $1.91K.
  • ADMA Biologics made up 0.01% of Inscription Capital's portfolio in Q2 2026, its #769 holding.
  • Inscription Capital first reported a position in ADMA Biologics in Q1 2026 and has held it in 2 quarters since.
  • Inscription Capital's ADMA Biologics position peaked at $121K in Q1 2026.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Inscription Capital's 13F filing for Q2 2026, filed 13 Aug 2026.